The purpose of this study is to learn about: * effects of living with COVID-19 and * how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan. In Group 1 the below participants were included in the study: * Patients of all ages. * Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021. * Cases of patients registered in the databases. In Group 2 the below participants were included in the study: * Participants who are 12 years or older. * Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022. Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19. The study will look at: * the nature of Covid-19 disease. * as well as the experiences of people receiving the nirmatrelvir-ritonavir. This study will help to: * understand what type of patients will need to be admitted to hospitals. * see severe results due to COVID 19 infection. * have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
Age range
0 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU)
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a diagnosis of COVID-19 that did not require ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a diagnosis of COVID-19 that required ICU
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
Timeframe: 01 January 2021 to 31 December 2021
Cohort 2: Characteristics Associated with Patients Receiving nirmatrelvir/ritonavir vs Patients Not Receiving nirmatrelvir/ritonavir
Timeframe: 01 January 2022 to 31 December 2022